William Kaye, MD
Endocrinology, Diabetes & Metabolism · West Palm Beach, FLNPI 1003820002
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $464,013 of the $514,687 with a category attached, or 90.2%. 58 manufacturers reported payments, led by Lilly USA, LLC at 48.0% of the total. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,161 payments — averaging $443.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$247K
- Novo Nordisk$147K
- Boehringer Ingelheim$78K
- AstraZeneca$15K
- Merck$7K
- Bayer$6K
- plus $14K from 52 others
Across 1,331 payments — averaging $598.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$276K
- Bayer$186K
- Eli Lilly$119K
- AbbVie$115K
- AstraZeneca$52K
- Abbott$20K
- plus $27K from 3 others
What the payments were for
- Consulting fees$7,1251%
- Speaking & faculty fees$464,01390%
- Travel & lodging$22,3024%
- Food & beverage$20,0564%
- Education$1130%
- Gifts$1,0780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$185,850
- MOUNJARO$127,912
- Ozempic$76,798
- RYBELSUS$49,451
- FARXIGA$14,605
- STEGLATRO$7,000
- Tresiba$6,630
- Kerendia$5,543
- Synthroid$3,225
- 25-OH Vitamin D ST AIA-Pack$2,156
- FREESTYLE LIBRE 3$918
- TU, AIA-PACK Calibrator Set$539
- TU, ST, AIA-PACK$539
- iLet Bionic Pancreas$437
- AFREZZA$381
- DEXCOM G7 GSS (161)$247
- EVENITY$241
- DEXCOM STELO GLUCOSE BIOSENSOR$146
- TWIIST$138
- MINIMED 780G$136
How this compares
$514,687 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 892 | $1,351,219 |
| JardianceEmpagliflozin | 386 | $514,418 |
| MounjaroTirzepatide | 391 | $502,234 |
| TrulicityDulaglutide | 133 | $176,108 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 148 | $134,192 |
| Tresiba Flextouch U-200Insulin Degludec | 85 | $97,507 |
| RybelsusSemaglutide | 45 | $89,314 |
| FarxigaDapagliflozin Propanediol | 70 | $89,289 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 107 | $86,716 |
| Tresiba Flextouch U-100Insulin Degludec | 118 | $81,403 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 116 | $70,616 |
| JanuviaSitagliptin Phosphate | 61 | $67,396 |
| KerendiaFinerenone | 34 | $58,276 |
| SynthroidLevothyroxine Sodium | 469 | $57,053 |
| ForteoTeriparatide | 13 | $56,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $146,711 | $1,453,834982 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Insulin Lispro | $246,961 | $755,175613 claims |
| Boehringer IngelheimJardiance, Tradjenta | $78,392 | $533,567402 claims |
| AstraZenecaFarxiga | $15,143 | $89,28970 claims |
| MerckJanuvia | $7,171 | $67,39661 claims |
| AbbVieSynthroid, Armour Thyroid | $3,775 | $59,859505 claims |
| BayerKerendia | $6,466 | $58,27634 claims |
| AmgenProlia | $1,170 | $18,79011 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $190 | $14,794690 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in West Palm Beach
- Barry HorowitzWest Palm Beach$628K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.